Aptose Biosciences Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Aug 25, 2025 · CIK: 882361
Sentiment: neutral
Topics: 8-K, corporate-actions, disclosure
Related Tickers: APTO
TL;DR
APTO filed an 8-K on 8/25 for events on 8/22 - check for votes, Reg FD, and financials.
AI Summary
Aptose Biosciences Inc. filed an 8-K on August 25, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial statements and exhibits as of August 22, 2025. The filing indicates a change in the company's reporting status or significant corporate events requiring immediate disclosure.
Why It Matters
This 8-K filing signals important corporate actions or disclosures by Aptose Biosciences Inc. that could impact investors and stakeholders.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor attention.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- August 22, 2025 (date) — Earliest event reported
- August 25, 2025 (date) — Date of report
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not provided in the provided text.
What is the nature of the Regulation FD Disclosure?
The filing lists 'Regulation FD Disclosure' as an item, suggesting that non-public material information may have been disclosed, but the content of this disclosure is not detailed in the provided text.
What financial statements and exhibits are included in this filing?
The filing states 'Financial Statements and Exhibits' are included, but the specific financial statements or exhibits are not detailed in the provided text.
What is the significance of the 'Date as of Change' being August 25, 2025?
The 'Date as of Change' being August 25, 2025, aligns with the filing date, indicating that the reported information pertains to events or changes effective on or around this date.
What was Aptose Biosciences Inc. formerly known as?
Aptose Biosciences Inc. was formerly known as LORUS THERAPEUTICS INC. and IMUTEC PHARMA INC., with name changes occurring on September 5, 2014, March 8, 1999, and January 13, 1997, respectively.
Filing Stats: 607 words · 2 min read · ~2 pages · Grade level 9.5 · Accepted 2025-08-25 17:00:31
Filing Documents
- f8k_082525.htm (8-K) — 18KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-25-005581.txt ( ) — 218KB
- gnw-20250101.xsd (EX-101.SCH) — 3KB
- gnw-20250101_def.xml (EX-101.DEF) — 25KB
- gnw-20250101_lab.xml (EX-101.LAB) — 35KB
- gnw-20250101_pre.xml (EX-101.PRE) — 24KB
- f8k_082525_htm.xml (XML) — 3KB
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On August 22, 2025, Aptose Biosciences Inc., or the "Corporation," held its reconvened Annual and Special Meeting of the shareholders of the Corporation (the "Meeting"). At the Meeting, shareholders voted in favor of all items of business, as indicated below: Proposal No. 2 - Appointment of Independent Registered Public Accounting Firm The Corporation's shareholders voted to approve the appointment of an independent registered public accounting firm of the Corporation for the fiscal year ended December 31, 2025. Votes For % Votes For Vote Against % Votes Against Abstain Broker Non-Votes 1,436,464 96.95 36,817 2.48 8,376 2
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On August 22, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. Exhibit No. Description of Exhibit 99.1 Press Release dated August 22, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: August 25, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer